A Study With GLPG1972 in Osteoarthritis Subjects

NCT03311009 | Completed Phase 1 FDA Drug

• 1 other identifier: GLPG1972-CL-104
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, double-blind, placebo-controlled, stratified, ascending dose, single center study, in three semi-sequential cohorts of 10 male and female subjects of nonchildbearing potential with Osteoarthritis (OA), administered GLPG1972 or placebo. Per cohort, 10 subjects will be randomized in a 4:1 allocation ratio to active treatment with GLPG1972 or matching placebo. In each cohort, OA subjects will be stratified for age (50- 64 years and 65-75 years) with a minimum of 2 of each sex per age group.

Conditions

Osteoarthritis

Outcome Measures

Primary Outcomes (10)

• Difference between GLPG1972 treated subjects and placebo subjects in the number of Adverse Events

  To assess safety and tolerability of GLPG1972 in OA patients

  From screening until the final follow up visit (day 50)

• Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal vital signs

  To assess safety and tolerability of GLPG1972 in OA patients

  From screening until the final follow up visit (day 50)

• Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal clinical laboratory evaluations

  To assess safety and tolerability of GLPG1972 in OA patients

  Screening, Days -1, 2, 4, 8, 9, 15, 22, 29, 43 and the final follow up visit (day 50)

• Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal physical examination

  To assess safety and tolerability of GLPG1972 in OA patients

  Screening, days -1, 1, 2, 8, 15, 22, 29, 43 and the final follow up visit (day 50

• Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal ECG

  To assess safety and tolerability of GLPG1972 in OA patients

  Screening, days 1, 2, 3, 4, 8, 15, 22, 29, 43 and the final follow up visit (day 50)

• Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal Holter assessment

  To assess safety and tolerability of GLPG1972 in OA patients

  Day -1 to days 1 and Day 10 to day 11

• The maximum observed plasma concentration of GLPG1972 (Cmax)

  To assess PK of GLPG1972 in OA patients

  Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43

• The time (tmax) to reach Cmax of GLPG1972

  To assess PK of GLPG1972 in OA patients

  Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43

• The plasma concentration of GLPG1972 24 after the last dose

  To assess PK of GLPG1972 in OA patients

  Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43

• The area under the plasma concentration time curve from time 0 until the last quantifieble dose

  To assess PK of GLPG1972 in OA patients

  Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43

Secondary Outcomes (1)

• Percentage reduction of neo-epitope ARGS vs baseline

  Days 1, 3, 6, 8, 10, 15, 22, 29, 43 and the final follow up visit (day 50)

Study Arms (2)

GLPG1972

EXPERIMENTAL

Drug: GLPG1972 cohort 1; Drug: GLPG1972 cohort 2; Drug: GLPG1972 cohort 3

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

GLPG1972 cohort 1 DRUG

GLPG1972 dose 1 provided as oral tablets q.d.

GLPG1972

GLPG1972 cohort 2 DRUG

GLPG1972 dose 2 provided as oral tablets q.d.

GLPG1972

GLPG1972 cohort 3 DRUG

GLPG1972 dose 3 provided as oral tablets q.d.

GLPG1972

Placebo DRUG

Matching placebo provided as oral tablets q.d.

Placebo

Eligibility Criteria

• Age: 50 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects of non-childbearing potential, 50-75 years of age on the date of signing the Informed Consent Form (ICF), inclusive extremes.
• Diagnosis of OA (knee and/or hip) made by their physician based on symptoms, clinical signs and documented historical imaging evidence.
• A body mass index (BMI) between 18.0 and 34.9 kg/m2, inclusive extremes.
• Judged to be in age-appropriate good health by the investigator based upon the results of a medical history, physical examination, vital signs and 12-lead ECG, and fasting clinical laboratory profile.
• Subjects with a stable chronic illness at least 3 months will be accepted subject to the investigator's judgment.

You may not qualify if:

• Administration of intraarticular glucocorticoid injections or hyaluronan injections in the last 3 months prior to study screening.
• Subjects who underwent or are on a waiting list for total hip or knee replacement and any other surgery planned during the study (up to Day 50).
• Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
• Positive serology for HBsAg or HCV antibody or history of hepatitis from any cause with the exception of hepatitis A.
• History of or a current immunosuppressive condition.
• Clinically significant serious, per investigator's discretion, and/or unstable illness in the 3 months before screening
• Renal function with an estimated creatinine clearance \< 60 mL/min based on the Cockcroft-Gault formula. Retesting is allowed once (see Section 5.2).
• Use of verapamil, diltiazem, amitriptyline, warfarin, acenocoumarol, phenobarbital and phenytoin, within 4 weeks before first study drug administration
• Consumption of herbal medications that are strong inhibitors and/or inducers of CYPs (e.g., St. John's Wort) and grapefruit/grapefruit products, Seville oranges, or any poppy seed, within 7 days prior to the first study drug administration.
• History of solid organ or hematopoietic cell transplantation.
• History of malignancy within the past 5 years.
• Clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction (e.g., QTcF ≥ 450 ms for males and QTcF ≥ 470 ms for females, or a known long QT syndrome).
• Significant blood loss (including blood donation \[\> 450 mL\]), or transfusion of any blood product within 12 weeks prior to screening

Sponsors & Collaborators

• Galapagos NV: lead

Study Sites (1)

Covance Daytona Beach

Daytona Beach, Florida, 32117, United States

Location

Related Publications (1)

• Chen L, Huang FL, Tang Q, Zhao ZK, Ye ZY, Liang JH. Targeted therapy for knee osteoarthritis: From basic to clinics. Medicine (Baltimore). 2025 Aug 15;104(33):e43686. doi: 10.1097/MD.0000000000043686.

  PMID: 40826764 DERIVED

MeSH Terms

Conditions

Osteoarthritis

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases

Study Officials

• Ann Fieuw, MD, MSc

  Galapagos NV

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 11, 2017
• First Posted: October 16, 2017
• Study Start: May 15, 2017
• Primary Completion: October 25, 2017
• Study Completion: October 25, 2017
• Last Updated: November 24, 2017

Record last verified: 2017-11

Locations

US (1)